Skip to main content
SpringerLink
Log in

Cancer of the Liver and Bile Ducts

  • Chapter
Oncology

  • 243 Accesses

Abstract

Hepatocellular carcinoma (HCC) is the fifth most common neoplasm in the world and the third most common cause of cancer death worldwide. More than 500,000 deaths per year are attributed to HCC, representing 10% of all deaths from cancer. In select areas of Asia and Africa, HCC is the most common cause of death due to cancer. The incidence in Europe and the United States is relatively low but is increasing. In Europe, HCC is now the leading cause of death among patients with cirrhosis. In the United States, epidemiologic studies have demonstrated a doubling of HCC incidence over the past two decades. This increase, which has been attributed to the increasing prevalence of chronic hepatitis C virus (HCV) infection, is expected to continue over the next two decades, given the lag time between the onset of chronic hepatitis and development of HCC.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Parkin DM, Bray F, Ferlay J, et al. Estimating the world cancer burden: GLOBOCAN 2000. Int J Cancer (Phila) 2001;94:153–156.

    Article  PubMed  CAS  Google Scholar 

  2. Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997;112:463–472.

    Article  PubMed  CAS  Google Scholar 

  3. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999;340:745–750.

    Article  PubMed  CAS  Google Scholar 

  4. Alberti A, Pontisso P. Hepatitis viruses as aetiological agents of hepatocellular carcinoma. Ital J Gastroenterol 1991;23:452–456.

    PubMed  CAS  Google Scholar 

  5. Beasley RP, Hwang LY, Lin CC, et al. Hepatocellular carcinoma and hepatitis B virus; a prospective study of 22,707 men in Taiwan. Lancet 1981;2:1129–1133.

    Article  PubMed  CAS  Google Scholar 

  6. Zhou XD, Tang ZY, Yang BH, et al. Experience of 1000 patients who underwent hepatectomy for small hepatocellular carcinoma. Cancer (Phila) 2001;91:1479–1486.

    Article  PubMed  CAS  Google Scholar 

  7. Chang MH, Chen CJ, Lai MS, et al. Universal hepatitis B vaccination in children. N Engl J Med 1997;336:1855–1859.

    Article  PubMed  CAS  Google Scholar 

  8. Change MH, Shau WY, Chen CJ, et al. The Taiwan Childhood Hepatoma Study Group: hepatitis B vaccination and hepatocellular carcinoma rates in boys and girls. JAMA 2000;284:3040–3042.

    Article  Google Scholar 

  9. WHO. Hepatitis C: global prevalence. Wkly Epidemiol Rec 1997;72:341–344.

    Google Scholar 

  10. Niederau C, Fischer R, Sonnenberg A, et al. Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis. N Engl J Med 1985;313:1256–62.

    Article  PubMed  CAS  Google Scholar 

  11. Sun Z, Lu P, Gail MH. Increased risk of hepatocellular carcinoma in male hepatitis B surface antigen carriers with chronic hepatitis who have detectable aflatoxin metabolite M1. Hepatology 1999;30:379–383.

    Article  PubMed  CAS  Google Scholar 

  12. Ozturk M. p53 mutation in hepatocellular carcinoma after aflatoxin exposure. Lancet 1991;338:1356–1359.

    Article  PubMed  CAS  Google Scholar 

  13. Farges O, Belghiti J, Kianmanesh R, et al. Portal vein embolization before right hepatectomy: prospective clinical trial. Ann Surg 2003;237:208–217.

    Article  PubMed  Google Scholar 

  14. Hemming AW, Reed AI, Howard RJ, et al. Preoperative portal vein embolization for extended hepatectomy. Ann Surg 2003;237:686–691.

    Article  PubMed  Google Scholar 

  15. Abdalla EK, Barnett CC, Doherty D, et al. Extended hepatectomy in patients with hepatobiliary malignancies with and without preoperative portal vein embolization. Arch Surg 2002;137:675–681.

    Article  PubMed  Google Scholar 

  16. Okuda K, Ohtsuki T, Obata H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer (Phila) 1985;56:918–928.

    Article  PubMed  CAS  Google Scholar 

  17. Bismuth H, Majno P. Hepatobiliary surgery. J Hepatol 2000;32:208–224.

    Article  PubMed  CAS  Google Scholar 

  18. Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 1999;39:1434–1440.

    Article  Google Scholar 

  19. Nagasue N, Uchida M, Makino Y, et al. Incidence and factors associated with intrahepatic recurrence following resection of hepatocellular carcinoma. Gastroenterology 1993;105:488–494.

    PubMed  CAS  Google Scholar 

  20. Ringe B, Pichlmayr R, Wittekind C, et al. Surgical treatment of hepatocellular carcinoma: experience with liver resection and transplantation in 198 patients. World J Surg 1991;15:270–285.

    Article  PubMed  CAS  Google Scholar 

  21. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693–699.

    Article  PubMed  CAS  Google Scholar 

  22. Bismuth H, Majno PE, Adam R. Liver transplantation for hepatocellular carcinoma. Semin Liver Dis 1999;19:311–322.

    Article  PubMed  CAS  Google Scholar 

  23. Jonas S, Bechstein WO, Steinmuller T, et al. Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology 2001;33:1080–1086.

    Article  PubMed  CAS  Google Scholar 

  24. Yao FY, Ferrell L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001;33:1394–1403.

    Article  PubMed  CAS  Google Scholar 

  25. Yao FY, Bass NM, Nikolai B, et al. Liver transplantation for hepatocellular carcinoma: analysis of survival according to the intention-to-treat principle and dropout from the waiting list. Liver Transplant 2002;8:873–883.

    Article  Google Scholar 

  26. Livraghi T, Giorgio A, Marin G, et al. Hepatocellular carcinoma and cirrhosis in 746 patients: long-term results of percutaneous ethanol injection. Radiology 1995;197:101–108.

    PubMed  CAS  Google Scholar 

  27. Lencioni R, Pinto F, Armillotta N, et al. Long-term results of percutaneous ethanol injection therapy for hepatocellular carcinoma in cirrhosis: a European experience. Eur Radiol 1997;7:514–519.

    Article  PubMed  CAS  Google Scholar 

  28. Arri S, Yamaoka Y, Futagawa S, et al. Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. Hepatology 2000;32:1224–1229.

    Article  Google Scholar 

  29. Lencioni RA, Allgaier HP, Cioni D, et al. Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. Radiology 2003;228:235–240.

    Article  PubMed  Google Scholar 

  30. Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 2002;35:519–524.

    Article  PubMed  Google Scholar 

  31. Bruix J, Llovet JM Castells A, et al. Transarterial embolization versus symptomatic treatment in patient with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. Hepatology 1998;27:1578–1583.

    Article  PubMed  CAS  Google Scholar 

  32. Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002;35:1164–1171.

    Article  PubMed  CAS  Google Scholar 

  33. Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002;359:1734–1739.

    Article  PubMed  Google Scholar 

  34. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003;37:429–442.

    Article  PubMed  CAS  Google Scholar 

  35. Chlebowski RT, Brzechwa-Adjukiewicz A, Cowden A, et al. Doxorubicin (75mg/m2) for hepatocellular carcinoma: clinical and pharmacokinetic results. Cancer Treat Rev 1984;68:487–491.

    CAS  Google Scholar 

  36. Lai CL, Wu PC, Chan GC, et al. Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial. Cancer (Phila) 1988;62:479–483.

    Article  PubMed  CAS  Google Scholar 

  37. Sciarrino E, Simonetti RG, Le Moli S, et al. Adriamycin treatment for hepatocellular carcinoma. Experience with 109 patients. Cancer (Phila) 1985;56:2751–2755.

    Article  PubMed  CAS  Google Scholar 

  38. Halm U, Etzrodt G, Schiefke I, et al. A phase II study of pegylated liposomal doxorubicin for treatment of advanced hepatocellular carcinoma. Ann Oncol 2000;11(1):113–114.

    Article  PubMed  CAS  Google Scholar 

  39. Hong RL, Tseng YL. A phase II and pharmacokinetic study of pegylated liposomal doxorubicin in patients with advanced hepatocellular carcinoma. Cancer Chemother Pharmacol 2003;51:433–438.

    PubMed  CAS  Google Scholar 

  40. Schmidinger M, Wenzel C, Locker GJ, et al. Pilot study with pegylated liposomal doxorubicin for advanced or unresectable hepatocellular carcinoma. Br J Cancer 2001;85:1850–1852.

    Article  PubMed  CAS  Google Scholar 

  41. Hochster HS, Green MD, Speyer J, et al. 4′-Epidoxorubicin (epirubicin): activity in hepatocellular carcinoma. J Clin Oncol 1985;3:1535–1540.

    PubMed  CAS  Google Scholar 

  42. Pohl J, Zuna I, Stremmel W, et al. Systemic chemotherapy with epirubicin for treatment of advanced or multifocal hepatocellular carcinoma. Chemotherapy 2001;47:359–365.

    Article  PubMed  CAS  Google Scholar 

  43. Patt YZ, Hoque A, Roh M, et al. Durable clinical and pathologic response of hepatocellular carcinoma to systemic and hepatic arterial administration of platinol, recombinant interferon alpha 2B, doxorubicin, and 5-fluorouracil: a communication. Am J Clin Oncol 1999;22:209–213.

    Article  PubMed  CAS  Google Scholar 

  44. Leung TW, Patt YZ, Lau WY, et al. Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma. Clin Cancer Res 1999;5:1676–1681.

    PubMed  CAS  Google Scholar 

  45. Malaguarnera M, Trovato G, Restuccia S, et al. Treatment of nonresectable hepatocellular carcinoma: review of the literature and meta-analysis. Adv Ther 1994;11:303–319.

    PubMed  CAS  Google Scholar 

  46. Simonetti RG, Liberati A, Angiolini C, et al. Treatment of hepatocellular carcinoma: a systematic review of randomized controlled trials. Ann Oncol 1997;8:117–136.

    Article  PubMed  CAS  Google Scholar 

  47. Mathurin P, Rixe O, Carbonell N, et al. Review article: Overview of medical treatments in unresectable hepatocellular carcinoma—an impossible meta-analysis? Aliment Pharmacol Ther 1998;12:111–126.

    Article  PubMed  CAS  Google Scholar 

  48. Jiang SY, Shyu RY, Yeh MY, et al. Tamoxifen inhibits hepatoma cell growth through an estrogen receptor independent mechanism. J Hepatol 1995;23:712–719.

    Article  PubMed  CAS  Google Scholar 

  49. Boix L, Bruix J, Castells A, et al. Sex hormone receptors in hepatocellular carcinoma. Is there a rationale for hormonal treatment? J Hepatol 1993;17:187–191.

    Article  PubMed  CAS  Google Scholar 

  50. Elba S, Giannuzzi V, Misciagna G, et al. Randomized controlled trial of tamoxifen versus placebo in inoperable hepatocellular carcinoma. Ital J Gastroenterol 1994;26:66–68.

    PubMed  CAS  Google Scholar 

  51. Martinez Cerezo FJ, Tomas A, Donoso L, et al. Controlled trial of tamoxifen in patients with advanced hepatocellular carcinoma. J Hepatol 1994;20:702–706.

    Article  PubMed  CAS  Google Scholar 

  52. Castells A, Bruix J, Bru C, et al. Treatment of hepatocellular carcinoma with tamoxifen: a double-blind placebo-controlled trial in 120 patients. Gastroenterology 1995;109:917–922.

    Article  PubMed  CAS  Google Scholar 

  53. Perrone F, Gallo C, Daniele B, et al. Tamoxifen in the treatment of hepatocellular carcinoma: 5-year results of the CLIP-1 multicentre randomised controlled trial. Curr Pharm Des 2002;8:1013–1019.

    Article  PubMed  CAS  Google Scholar 

  54. Liu CL, Fan ST, Ng IO, et al. Treatment of advanced hepatocellular carcinoma with tamoxifen and the correlation with expression of hormone receptors: a prospective randomized study. Am J Gastroenterol 2000;95:218–222.

    Article  PubMed  CAS  Google Scholar 

  55. Chow PK, Tai BC, Tan CK, et al. High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: a multicenter randomized controlled trial. Hepatology 2002;36(5):1221–1226.

    Article  PubMed  CAS  Google Scholar 

  56. Chao Y, Chan WK, Huang YS, et al. Phase II study of flutamide in the treatment of hepatocellular carcinoma. Cancer (Phila) 1996;77:635–639.

    Article  PubMed  CAS  Google Scholar 

  57. Colleoni M, Nelli P, Vicario G, et al. Megestrol acetate in unresectable hepatocellular carcinoma. Tumori 1995;81(5):351–353.

    PubMed  CAS  Google Scholar 

  58. Chao Y, Chan WK, Wang SS, et al. Phase II study of megestrol acetate in the treatment of hepatocellular carcinoma. J Gastroenterol Hepatol 1997;12:277–281.

    PubMed  CAS  Google Scholar 

  59. Raderer M, Hejna MH, Muller C, et al. Treatment of hepatocellular cancer with the long acting somatostatin analog lanreotide in vitro and in vivo. Int J Oncol 2000;16:1197–1201.

    PubMed  CAS  Google Scholar 

  60. Kouroumalis E, Skordilis P, Thermos K, et al. Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study. Gut 1998;42:442–447.

    Article  PubMed  CAS  Google Scholar 

  61. Pan DY, Qiao JG, Chen JW, et al. Tamoxifen combined with octreotide or regular chemotherapeutic agents in treatment of primary liver cancer: a randomized controlled trial. Hepatobiliary Pancreat Dis Int 2003;2:211–215.

    PubMed  CAS  Google Scholar 

  62. Huang YH, Wu JC, Lui WY, et al. Prospective case-controlled trial of adjuvant chemotherapy after resection of hepatocellular carcinoma. World J Surg 2000;24:551–555.

    Article  PubMed  CAS  Google Scholar 

  63. Schwartz JD, Schwartz M, Mandeli J, et al. Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomised clinical trials. Lancet Oncol 2002;3:593–603.

    Article  PubMed  Google Scholar 

  64. Patel T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 2001;33:1353–1357.

    Article  PubMed  CAS  Google Scholar 

  65. Patel T. Worldwide trends in mortality from biliary tract malignancies. BMC Cancer 2002;2:10.

    Article  PubMed  Google Scholar 

  66. Khan SA, Taylor-Robinson SD, Toledano MB, et al. Changing international trends in mortality rates for liver, biliary and pancreatic tumours. J Hepatol 2002;37:806–813.

    Article  PubMed  Google Scholar 

  67. Terada T, Kida T, Nakanuma Y, et al. Intrahepatic cholangiocarcinomas associated with nonbiliary cirrhosis. A clinicopathologic study. J Clin Gastroenterol 1994;18:335–342.

    Article  PubMed  CAS  Google Scholar 

  68. Bergquist A, Glaumann H, Persson B, et al. Risk factors and clinical presentation of hepatobiliary carcinoma in patients with primary sclerosing cholangitis: a case-control study. Hepatology 1998;27:311–316.

    Article  PubMed  CAS  Google Scholar 

  69. Bergquist A, Ekbom A, Olsson R, et al. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol 2002;36:321–327.

    Article  PubMed  Google Scholar 

  70. Khan SA, Davidson BR, Goldin R, et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut 2002;51(suppl 6):VI1–VI9.

    PubMed  Google Scholar 

  71. Okuda K, Nakanuma Y, Miyazaki M. Cholangiocarcinoma: recent progress. Part 1: epidemiology and etiology. J Gastroenterol Hepatol 2002;17:1049–1055.

    Article  PubMed  Google Scholar 

  72. Kobayashi M, Ikeda K, Saitoh S, et al. Incidence of primary cholangiocellular carcinoma of the liver in Japanese patients with hepatitis C virus-related cirrhosis. Cancer (Phila) 2000;88:2471–2477.

    Article  PubMed  CAS  Google Scholar 

  73. Fong YY, Chan WC. Bacterial production of di-methyl nitrosamine in salted fish. Nature (Lond) 1973;243:421–422.

    Article  PubMed  CAS  Google Scholar 

  74. Herrold KM. Histogenesis of malignant liver tumors induced by dimethylnitrosamine. An experimental study in Syrian hamsters. J Natl Cancer Inst 1967;39:1099–1111.

    PubMed  CAS  Google Scholar 

  75. Jaiswal M, LaRusso NF, Gores GJ. Nitric oxide in gastrointestinal epithelial cell carcinogenesis: linking inflammation to oncogenesis. Am J Physiol Gastrointest Liver Physiol 2001;281:G626–G634.

    PubMed  CAS  Google Scholar 

  76. Jaiswal M, LaRusso NF, Shapiro RA, et al. Nitric oxide-mediated inhibition of DNA repair potentiates oxidative DNA damage in cholangiocytes. Gastroenterology 2001;120:190–199.

    Article  PubMed  CAS  Google Scholar 

  77. Mannick JB, Hausladen A, Liu L, et al. Fas-induced caspase denitrosylation. Science 1999;284:651–654.

    Article  PubMed  CAS  Google Scholar 

  78. Jaiswal M, LaRusso NF, Burgart LJ, et al. Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism. Cancer Res 2000;60:184–190.

    PubMed  CAS  Google Scholar 

  79. Parkin DM, Srivatanakul P, Khlat M, et al. Liver cancer in Thailand. I. A case-control study of cholangiocarcinoma. Int J Cancer 1991;48:323–328.

    Article  PubMed  CAS  Google Scholar 

  80. Rao CV, Indranie C, Simi B, et al. Chemopreventive properties of a selective inducible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with celecoxib, a selective cyclooxygenase-2 inhibitor. Cancer Res 2002;62:165–170.

    PubMed  CAS  Google Scholar 

  81. Kisley LR, Barrett BS, Bauer AK, et al. Genetic ablation of inducible nitric oxide synthase decreases mouse lung tumorigenesis. Cancer Res 2002;62:6850–6856.

    PubMed  CAS  Google Scholar 

  82. Yoon JH, Higuchi H, Werneburg NW, et al. Bile acids induce cyclooxygenase-2 expression via the epidermal growth factor receptor in a human cholangiocarcinoma cell line. Gastroenterology 2002;122:985–993.

    Article  PubMed  CAS  Google Scholar 

  83. Gupta RA, Dubois RN. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer 2001;1:11–21.

    Article  PubMed  CAS  Google Scholar 

  84. Yoon JH, Werneburg NW, Higuchi H, et al. Bile acids inhibit Mcl-1 protein turnover via an epidermal growth factor receptor/Raf-1-dependent mechanism. Cancer Res 2002;62:6500–6505.

    PubMed  CAS  Google Scholar 

  85. Okaro AC, Deery AR, Hutchins RR, et al. The expression of antiapoptotic proteins Bcl-2, Bcl-X(L), and Mcl-1 in benign, dysplastic, and malignant biliary epithelium. J Clin Pathol 2001;54:927–932.

    PubMed  CAS  Google Scholar 

  86. Pichlmayr R, Lamesch P, Weimann A, et al. Surgical treatment of cholangiocellular carcinoma. World J Surg 1995;19:83–88.

    Article  PubMed  CAS  Google Scholar 

  87. Colombari R, Tsui WM. Biliary tumors of the liver. Semin Liver Dis 1995;15:402–413.

    PubMed  CAS  Google Scholar 

  88. Lieser MJ, Barry MK, Rowland C, et al. Surgical management of intrahepatic cholangiocarcinoma: a 31-year experience. J Hepatobiliary Pancreat Surg 1998;5:41–47.

    Article  PubMed  CAS  Google Scholar 

  89. Liver Cancer Study Group of Japan. Classification of primary liver cancer. Tokyo: Kanehara-Shuppan, 1997.

    Google Scholar 

  90. Kang YK, Kim WH, Lee HW, et al. Mutation of p53 and K-ras, and loss of heterozygosity of APC in intraphepatic cholangiocarcinoma. Lab Invest 1999;79(4):477–483.

    PubMed  CAS  Google Scholar 

  91. Ohashi K, Nakajima Y, Kanehiro H, et al. Ki-ras mutations and p53 protein expressions in intrahepatic cholangiocarcinomas: relation to gross tumor morphology. Gastroenterology 1995;109:1612–1617.

    Article  PubMed  CAS  Google Scholar 

  92. Roayaie S, Guarrera JV, Ye MQ, et al. Aggressive surgical treatment of intrahepatic cholangiocarcinoma: predictors of outcomes. J Am Coll Surg 1998;187:365–372.

    Article  PubMed  CAS  Google Scholar 

  93. Chou FF, Sheen-Chen SM, Chen YS, et al. Surgical treatment of cholangiocarcinoma. Hepatogastroenterology 1997;44:760–765.

    PubMed  CAS  Google Scholar 

  94. Nakajima T, Kondo Y, Miyazaki M, et al. A histopathologic study of 102 cases of intrahepatic cholangiocarcinoma: histologic classification and modes of spreading. Hum Pathol 1988;19:1228–1234.

    Article  PubMed  CAS  Google Scholar 

  95. Inohue K, Makuuchi M, Takayama T, et al. Long-term survival and prognostic factors in the surgical treatment of mass-forming type cholangiocarcinoma. Surgery (St. Louis) 2000;127:498–505.

    Google Scholar 

  96. Chu KM, Lai ECS, Al-Hadeedi S, et al. Intrahepatic cholangiocarcinoma. World J Surg 1997;21:301–306.

    Article  PubMed  CAS  Google Scholar 

  97. Burke EC, Jarnagin WR, Hochwald SN, et al. Hilar cholangiocarcinoma: patterns of spread, the importance of hepatic resection for curative operation, and a presurgical clinical staging system. Ann Surg 1998;228:385–394.

    Article  PubMed  CAS  Google Scholar 

  98. Weinbren K, Mutum SS. Pathological aspects of cholangiocarcinoma. J Pathol 1983;139:217–238.

    Article  PubMed  CAS  Google Scholar 

  99. Sako K, Seitzinger GL, Garside E. Carcinoma of the extrahepatic bile ducts: review of the literature and report of six cases. Surgery (St. Louis) 1957;41:416–437.

    PubMed  CAS  Google Scholar 

  100. Pitt HA, Dooley WC, Yeo CJ, et al. Malignancies of the biliary tree. Curr Probl Surg 1995;32:1–90.

    Article  PubMed  CAS  Google Scholar 

  101. Jarnagin WR, Fong Y, DeMatteo RP, et al. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg 2001;234:507–519.

    Article  PubMed  CAS  Google Scholar 

  102. Nimura Y Kamiya J, Kondo S, et al. Aggressive preoperative management and extended surgery for hilar cholangiocarcinoma: Nagoya experience. J Hepatobiliary Pancreat Surg 2000;7:155–162.

    Article  PubMed  CAS  Google Scholar 

  103. Kawasaki S, Makuuchi M, Miyagawa S, et al. Radical operation after portal embolization for tumor of the hilar bile duct. J Am Coll Surg 1994;178:480–486.

    PubMed  CAS  Google Scholar 

  104. Hochwald SN, Burke EC, Jarnagin WR, et al. Association of preoperative biliary stenting with increased postoperative infectious complications in proximal cholangiocarcinoma. Arch Surg 1999;134:261–266.

    Article  PubMed  CAS  Google Scholar 

  105. Gallinger S, Gluckman D, Langer B. Proximal bile duct cancer. Adv Surg 1990;23:89–118.

    PubMed  CAS  Google Scholar 

  106. Cameron JL, Pitt HA, Zinner MJ, et al. Management of proximal cholangiocarcinomas by surgical resection and radiotherapy. Am J Surg 1990;159:91–97.

    Article  PubMed  CAS  Google Scholar 

  107. Gerhards MF, van Gulik TM, de Wit LT, et al. Evaluation of morbidity and mortality after resection for hilar cholangiocarcinoma — a single center experience. Surgery (St. Louis 2000;127:395–404.

    Article  PubMed  CAS  Google Scholar 

  108. Mulholland MW, Yahanda A, Yeo CJ. Multidisciplinary management of perihilar bile duct cancer. J Am Coll Surg 2001;193:440–447.

    Article  PubMed  CAS  Google Scholar 

  109. Tabata M, Kawarada Y, Yokoi H, et al. Surgical treatment for hilar cholangiocarcinoma. J Hepatobiliary Pancreat Surg 2000;7:148–154.

    Article  PubMed  CAS  Google Scholar 

  110. Gazzaniga GM, Ciferri E, Bagarolo C, et al. Primitive hepatic hilum neoplasm. J Surg Oncol 1993;3:140–146.

    Article  CAS  Google Scholar 

  111. Gazzaniga GM, Filauro M, Bagarolo C, et al. Surgery for hilar cholangiocarcinoma: an Italian experience. J Hepatobiliary Pancreat Surg 2000;7:122–127.

    Article  PubMed  CAS  Google Scholar 

  112. Tsao JI, Nimura Y, Kamiya J, et al. Management of hilar cholangiocarcinoma: comparison of an American and a Japanese experience. Ann Surg 2000;232:166–174.

    Article  PubMed  CAS  Google Scholar 

  113. Nimura Y, Haykawa N, Kamiya J, et al. Hilar cholangiocarcinoma: surgical anatomy and curative resection. J Hepatobiliary Pancreat Surg 1995;2:239–248.

    Article  Google Scholar 

  114. Kawarada Y, Suzuki H, Mizumoto R. Surgical treatment of hilar carcinoma of the bile duct, with special reference to anatomy of the hepatic hilum and caudate lobe. Jpn J Gastroenterol Surg 1984;17:1684–1688.

    Google Scholar 

  115. Nimura Y, Hayakawa N, Kamiya J, et al. Hepatic segmentectomy with caudate lobe resection for bile duct carcinoma of the hepatic hilus. World J Surg 1990;14:535–543.

    Article  PubMed  CAS  Google Scholar 

  116. Ogura Y, Mizumoto R, Tabata M. Surgical treatment of carcinoma of the hepatic duct confluence: analysis of 55 resected carcinomas. World J Surg 1993;17:85–92.

    Article  PubMed  CAS  Google Scholar 

  117. Sugiura Y, Nakamura S, Iisda S, et al. Extensive resection of the bile ducts combined with liver resection for cancer of the main hepatic duct junction: a cooperative study of the Keio Bile Duct Cancer Study Group. Surgery (St/Louis) 1994;115:445–451.

    PubMed  CAS  Google Scholar 

  118. Farley DR, Weaver AL, Nagorney DM. Natural history of unresected cholangiocarcinoma: patient outcome after noncurative intervention. Mayo Clin Proc 1995;70:425–429.

    PubMed  CAS  Google Scholar 

  119. Lee SG, Lee YJ, Park KM. One hundred and eleven liver resections for hilar bile duct cancer. J Hepatobiliary Pancreat Surg 2000;7:135–141.

    Article  PubMed  CAS  Google Scholar 

  120. Neuhaus P, Jonas S, Bechstein WO, et al. Extended resections for hilar cholangiocarcinoma. Ann Surg 1999;230:808–818

    Article  PubMed  CAS  Google Scholar 

  121. Launois B, Reding R, Lebeau G. Surgery for hilar cholangiocarcinoma: French experience in a collective survey of 552 extrahepatic bile duct cancers. J Hepatobiliary Pancreat Surg 2000;7:128–134.

    Article  PubMed  CAS  Google Scholar 

  122. Rea DJ, Munoz-Juarez M, Farnell MB, et al. Major hepatic resection for hilar cholangiocarcinoma: analysis of 46 patients. Arch Surg 2004;139:514–525.

    Article  PubMed  Google Scholar 

  123. Glimelius B, Hoffman K, Sjoden PO, et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 1996;7:593–600.

    PubMed  CAS  Google Scholar 

  124. Falkson G, MacIntyre JM, Moertel CG. Eastern Cooperative Oncology Group experience with chemotherapy for inoperable gallbladder and bile duct cancer. Cancer (Phila) 1984;54:965–969.

    Article  PubMed  CAS  Google Scholar 

  125. Takada T, Kato H, Matsushiro T, et al. Comparison of 5-fluorouracil, doxorubicin and mitomycin C with 5-fluorouracil alone in the treatment of pancreatic-biliary carcinomas. Oncology 1994;51:396–400.

    PubMed  CAS  Google Scholar 

  126. Chen JS, Jan YY, Lin YC, et al. Weekly 24h infusion of high-dose 5-fluorouracil and leucovorin in patients with biliary tract carcinomas. Anti-Cancer Drugs 1998;9:393–397.

    Article  PubMed  CAS  Google Scholar 

  127. Raderer M, Hejna MH, Valencak JB, et al. Two consecutive phase II studies of 5-fluorouracil/leucovorin/mitomycin C and of gemcitabine in patients with advanced biliary cancer. Oncology 1999;56:177–180.

    Article  PubMed  CAS  Google Scholar 

  128. Chen JS, Lin YC, Jan YY, et al. Mitomycin C with weekly 24-h infusion of high-dose 5-fluorouracil and leucovorin in patients with biliary tract and periampullar carcinomas. Anticancer Drugs 2001;12(4):339–343.

    Article  PubMed  CAS  Google Scholar 

  129. Polyzos A, Nikou G, Giannopoulos A, et al. Chemotherapy of biliary tract cancer with mitomycin-C and 5-fluorouracil biologically modulated by folinic acid. A phase II study. Ann Oncol 1996;7:644–645.

    PubMed  CAS  Google Scholar 

  130. Harvey JH, Smith FP, Schein PS. 5-Fluorouracil, mitomycin, and doxorubicin (FAM) in carcinoma of the biliary tract. J Clin Oncol 1984;2:1245–1248.

    PubMed  CAS  Google Scholar 

  131. Castro MP. Efficacy of gemcitabine in the treatment of patients with gallbladder carcinoma: a case report. Cancer (Phila) 1998;82:639–641.

    Article  PubMed  CAS  Google Scholar 

  132. Gallardo J, Fodor M, Gamargo C, et al. Efficacy of gemcitabine in the treatment of patients with gallbladder carcinoma: a case report. Cancer (Phila) 1998;83:2419–2421.

    Article  PubMed  CAS  Google Scholar 

  133. Tsavaris N, Kosmas C, Gouveris P, et al. Weekly gemcitabine for the treatment of biliary tract and gallbladder cancer. Invest New Drugs 2004;22:193–198.

    Article  PubMed  CAS  Google Scholar 

  134. Kubicka S, Rudolph KL, Tietze MK, et al. Phase II study of systemic gemcitabine chemotherapy for advanced unresectable hepatobiliary carcinomas. Hepato-Gastroenterology 2001;48:783–789.

    PubMed  CAS  Google Scholar 

  135. Gallardo JO, Rubio B, Fodor M, et al. A phase II study of gemcitabine in gallbladder carcinoma. Ann Oncol 2001;12:1403–1406.

    Article  PubMed  CAS  Google Scholar 

  136. Penz M, Kornek GV, Raderer M, et al. Phase II trial of twoweekly gemcitabine in patients with advanced biliary tract cancer. Ann Oncol 2001;12:183–186.

    Article  PubMed  CAS  Google Scholar 

  137. Teufel A, Lehnert T, Stremmel W, et al. Chemotherapy with gemcitabine in patients with advanced gallbladder carcinoma. Z Gastroenterol 2000;38:909–912.

    Article  PubMed  CAS  Google Scholar 

  138. Metzger J, Sauerbruch T, Ko Y, et al. Phase II trial of gemcitabine in gallbladder and biliary tract carcinomas. Onkologie 1998;21:232–234.

    Article  Google Scholar 

  139. Valencak J, Kornek GV, Raderer M, et al. Gemcitabine for the treatment of advanced biliary tract carcinomas: evaluation of two different dose regimens. Onkologie 1999;22:498–501.

    Article  Google Scholar 

  140. Murad AM, Guimaraes RC, Aragao BC, et al. Phase II trial of the use of gemcitabine and 5-fluorouracil in the treatment of advanced pancreatic and biliary tract cancer. Am J Clin Oncol 2003;26:151–154.

    Article  PubMed  CAS  Google Scholar 

  141. Boxberger F, Jungert B, Brueckl V, et al. Palliative chemotherapy with gemcitabine and weekly high-dose 5-fluorouracil as 24-h infusion in metastatic biliary tract and gall bladder adenocarcinomas. Anticancer Drugs 2003;14:87–90.

    Article  PubMed  CAS  Google Scholar 

  142. Malik IA, Aziz Z, Zaidi SH, et al. Gemcitabine and cisplatin is a highly effective combination chemotherapy in patients with advanced cancer of the gallbladder. Am J Clin Oncol 2003;26:174–177.

    Article  PubMed  CAS  Google Scholar 

  143. Ravry MJR, Omura GA, Bartolucci AA, et al. Phase II evaluation of cisplatin in advanced hepatocellular carcinoma and cholangiocarcinoma: a Southeastern Cancer Study Group Trial. Cancer Treat Rep 1986;70:311–312.

    PubMed  CAS  Google Scholar 

  144. Okada S, Ishii H, Nose H, et al. A phase II study of cisplatin in patients with biliary tract carcinoma. Oncology 1994;51:515–517.

    Article  PubMed  CAS  Google Scholar 

  145. Ducreux M, Rougier P, Fandi A, et al. Effective treatment of advanced biliary tract carcinoma using 5-fluorouracil continuous infusion with cisplatin. Ann Oncol 1998;9:653–656.

    Article  PubMed  CAS  Google Scholar 

  146. Taieb J, Mitry E, Boige V, et al. Optimization of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of leucovorin, 5-FU and cisplatin (LV5FU2-P regimen) in patients with biliary tract carcinoma. Ann Oncol 2002;13:1192–1196.

    Article  PubMed  CAS  Google Scholar 

  147. Caroli-Bosc FX, Van Laethem JL, Michel P, et al. A weekly 24-h infusion of high-dose 5-fluorouracil (5-FU) + leucovorin and bi-weekly cisplatin (CDDP) was active and well tolerated in patients with non-colon digestive carcinomas. Eur J Cancer 2001;37:1828–1832.

    Article  PubMed  CAS  Google Scholar 

  148. Sanz-Altamira PM, Ferrante K, Jenkins RL, et al. A phase II trial of 5-fluorouracil, leucovorin, and carboplatin in patients with unresectable biliary tree carcinoma. Cancer (Phila) 1998;82:2321–2325.

    Article  PubMed  CAS  Google Scholar 

  149. Nehls O, Klump B, Arkenau HT, et al. Oxaliplatin, fluorouracil and leucovorin for advanced biliary system adenocarcinomas: a prospective phase II trial. Br J Cancer 2002;87:702–704.

    Article  PubMed  CAS  Google Scholar 

  150. Morizane C, Okada S, Okusaka T, et al. Phase II study of cisplatin, epirubicin, and continuous-infusion 5-fluorouracil for advanced biliary tract cancer. Oncology 2003;64:475–476.

    Article  PubMed  Google Scholar 

  151. Ellis PA, Norman A, Hill A, et al. Epirubicin, cisplatin and infusional 5-fluorouracil (5-FU) (ECF) in hepatobiliary tumours. Eur J Cancer 1995;31A:1594–1598.

    Article  PubMed  CAS  Google Scholar 

  152. Patt YZ, Hassan MM, Lozano RD, et al. Phase II trial of cisplatin, interferon alpha-2b, doxorubicin, and 5-fluorouracil for biliary tract cancer. Clin Cancer Res 2001;7:3375–3380.

    PubMed  CAS  Google Scholar 

  153. Alberts SR, Fishkin PA, Burgart LJ, et al. CPT-11 for bile-duct and gallbladder carcinoma: a phase II North Central Cancer Treatment Group (NCCTG) study. Int J Gastrointest Cancer 2002;32:107–114.

    Article  PubMed  CAS  Google Scholar 

  154. Sanz-Altamira PM, O’Reilly E, Stuart KE, et al. A phase II trial of inrinotecan (CPT-11) for unresectable biliary tree carcinoma. Ann Oncol 2001;12:501–504.

    Article  PubMed  CAS  Google Scholar 

  155. Papakostas P, Kouroussis C, Androulakis N, et al. First-line chemotherapy with docetaxel for unresectable or metastatic carcinoma of the biliary tract. A multicentre phase II study. Eur J Cancer 2001;37:1833–1838.

    Article  PubMed  CAS  Google Scholar 

  156. Jones DV Jr, Lozano R, Hoque A, Markowitz A, Patt YZ. Phase II study of paclitaxel therapy for unresectable biliary tree carcinomas. J Clin Oncol 1996;14:2306–2310.

    PubMed  CAS  Google Scholar 

  157. Takada T, Amano H, Yasuda H, et al. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer (Phila) 2002;95(8):1685–1689.

    Article  PubMed  Google Scholar 

  158. Todoroki T, Ohara K, Kawamoto T, et al. Benefits of adjuvant radiotherapy after radical resection of locally advanced main hepatic duct carcinoma. Int J Radiat Oncol Biol Phys 2000;46:581–587.

    Article  PubMed  CAS  Google Scholar 

  159. Gonzalez D, Gerard JP, Maners AW, et al. Results of radiation therapy in carcinoma of the proximal bile ducts (Klatskin tumor). Semin Liver Dis 1990;10:131–141.

    Google Scholar 

  160. Cameron JL, Pitt HA, Zinner MJ, et al. Management of proximal cholangiocarcinomas by surgical resection and radiotherapy. Am J Surg 1990;159:91–98.

    Article  PubMed  CAS  Google Scholar 

  161. Pitt HA, Nakeeb A, Abrams RA, et al. Perihilar cholangiocarcinoma: postoperative radiotherapy does not improve survival. Ann Surg 1995;221:778–798.

    Article  Google Scholar 

  162. Wayne JD, Lauwers GY, Ikai I, et al. Perioperative predictors of survival after resection of small hepatocellular carcinomas. Ann Surg 2002;235:722–731.

    Article  PubMed  Google Scholar 

  163. Poon RTP, Ng IOL, Fan ST, et al. Clinicopathologic features of long-term survivors and disease-free survivors after resection of hepatocellular carcinoma: a study of a prospective cohort. J Clin Oncol 2001;19:3037–3044.

    PubMed  CAS  Google Scholar 

  164. Fong Y, Sun RL, Jarnagin W, et al. An analysis of 412 cases of hepatocellular carcinoma at a western center. Ann Surg 1999;229:790–800.

    Article  PubMed  CAS  Google Scholar 

  165. Lise M, Bacchetti S, Da Pian, P, et al. Prognostic factors affecting long term outcome after liver resection for hepatocellular carcinoma: results in a series of 100 Italian patients. Cancer (Phila) 1998;82:1028–1036.

    Article  PubMed  CAS  Google Scholar 

  166. Mazziotti A, Frazi GL, Cavallari A. Surgical treatment of hepatocellular carcinoma on cirrhosis: a western experience. Hepatogastroenterology 1998;45:1281–1287.

    PubMed  Google Scholar 

  167. Takenaka K, Kawahara N, Yamamoto K, et al. Results of 280 liver resections for hepatocellular carcinoma. Arch Surg 1996;131:71–76.

    PubMed  CAS  Google Scholar 

  168. Vauthey JN, Klimstra D, Franceschi D, et al. Factors affecting long-term outcome after hepatic resection for hepatocellular carcinoma. Am J Surg 1995;169:28–34.

    Article  PubMed  CAS  Google Scholar 

  169. Kawasaki S, Makuuchi M, Miyagawa S, et al. Results of hepatic resection for hepatocellular carcinoma. World J Surg 1995;19:31–34.

    Article  PubMed  CAS  Google Scholar 

  170. Yang TS, Lin YC, Chen JS, et al. Phase II study of gemcitabine in patients with advanced hepatocellular carcinoma. Cancer (Phila) 2000;89:750–756.

    Article  PubMed  CAS  Google Scholar 

  171. Fuchs CS, Clark JW, Ryan DP, et al. A phase II trial of gemcitabine in patients with advanced hepatocellular carcinoma. Cancer (Phila) 2002;94:3186–3191.

    Article  PubMed  CAS  Google Scholar 

  172. Guan Z, Wang Y, Maoleekoonpairoj S, et al. Prospective randomised phase II study of gemcitabine at standard or fixed dose rate schedule in unresectable hepatocellular carcinoma. Br J Cancer 2003;89:1865–1869.

    Article  PubMed  CAS  Google Scholar 

  173. Ulrich-Pur H, Kornek GV, Fiebiger W, et al. Treatment of advanced hepatocellular carcinoma with biweekly high-dose gemcitabine. Oncology 2001;60:313–315.

    Article  PubMed  CAS  Google Scholar 

  174. Yang TS, Wang CH, Hsieh RK, et al. Gemcitabine and doxorubicin for the treatment of patients with advanced hepatocellular carcinoma: a phase I–II trial. Ann Oncol 2002;13:1771–1778.

    Article  PubMed  CAS  Google Scholar 

  175. Taieb J, Bonyhay L, Golli L, et al. Gemcitabine plus oxaliplatin for patients with advanced hepatocellular carcinoma using two different schedules. Cancer (Phila) 2003;98:2664–2670.

    Article  PubMed  CAS  Google Scholar 

  176. Zaniboni A, Simoncini E, Marpicati P, et al. Phase II study of 5-fluorouracil (5-FU) and high dose folinic acid (HDFA) in hepatocellular carcinoma. Br J Cancer 1988;57:319.

    PubMed  CAS  Google Scholar 

  177. van Eeden H, Falkson G, Burger W, et al. 5-Fluorouracil and leucovorin in hepatocellular carcinoma. Ann Oncol 1992;3:404–405.

    PubMed  Google Scholar 

  178. Tetef M, Doroshow J, Akman S, et al. 5-Fluorouracil and high-dose calcium leucovorin for hepatocellular carcinoma: a phase II trial. Cancer Invest 1995;13:460–463.

    Article  PubMed  CAS  Google Scholar 

  179. Porta C, Moroni M, Nastasi G, et al. 5-Fluorouracil and d,l-leucovorin calcium are active to treat unresectable hepatocellular carcinoma patients: preliminary results of a phase II study. Oncology 1995;52:487–491.

    PubMed  CAS  Google Scholar 

  180. Gebbia V, Maiello E, Serravezza G, et al. 5-Fluorouracil plus high dose levofolinic acid and oral hydroxyurea for the treatment of primary hepatocellular carcinomas: results of a phase II multicenter study of the Southern Italy Oncology Group (G.O.I.M.). Anticancer Res. 1999;19:1407–1410.

    PubMed  CAS  Google Scholar 

  181. Stuart K, Tessitore J, Huberman M. 5-Fluorouracil and alphainterferon in hepatocellular carcinoma. Am J Clin Oncol 1996;19:136–139.

    Article  PubMed  CAS  Google Scholar 

  182. Patt YZ, Jones DV, Hoque A, et al. Phase II trial of intravenous fluorouracil and subcutaneous interferon alfa-2b for biliary tract cancer. J Clin Oncol 1996;14:2311–2315.

    PubMed  CAS  Google Scholar 

  183. Mani S, Schiano T, Garcia JC, et al. Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced hepatocellular carcinoma. Invest New Drugs 1998;16:279–283.

    Article  PubMed  CAS  Google Scholar 

  184. Llovet JM, Ruff P, Tassopoulos N, et al. A phase II trial of oral eniluracil/5-fluorouracil in patients with inoperable hepatocellular carcinoma. Eur J Cancer 2001;37:1352–1358.

    Article  PubMed  CAS  Google Scholar 

  185. Benson AB III, Mitchell E, Abramson N, et al. Oral eniluracil/5-fluorouracil in patients with inoperable hepatocellular carcinoma. Ann Oncol 2002;13:576–581.

    Article  PubMed  Google Scholar 

  186. Falkson G, Ryan LM, Johnson LA, et al. A random phase II study of mitoxantrone and cisplatin in patients with hepatocellular carcinoma. An ECOG study. Cancer (Phila) 1987;60:2141–2145.

    Article  PubMed  CAS  Google Scholar 

  187. Okada S, Okazaki N, Nose H, et al. A phase 2 study of cisplatin in patients with hepatocellular carcinoma. Oncology 1993;50:22–26.

    PubMed  CAS  Google Scholar 

  188. Tanioka H, Tsuji A, Morita S, et al. Combination chemotherapy with continuous 5-fluorouracil and low-dose cisplatin infusion for advanced hepatocellular carcinoma. Anticancer Res 2003;23:1891–1897.

    PubMed  CAS  Google Scholar 

  189. Komorizono Y, Kohara K, Oketani M, et al. Systemic combined chemotherapy with low dose of 5-fluorouracil, cisplatin, and interferon-alpha for advanced hepatocellular carcinoma: a pilot study. Dig Dis Sci 2003;48:877–881.

    Article  PubMed  CAS  Google Scholar 

  190. Boucher E, Corbinais S, Brissot P, et al. Treatment of hepatocellular carcinoma (HCC) with systemic chemotherapy combining epirubicin, cisplatinum and infusional 5-fluorouracil (ECF regimen). Cancer Chemother Pharmacol 2002;50:305–308.

    Article  PubMed  CAS  Google Scholar 

  191. Alexandre J, Tigaud JM, Gross-Goupil M, et al. Combination of topotecan and oxaliplatin in inoperable hepatocellular cancer patients. Am J Clin Oncol 2002;25:198–203.

    Article  PubMed  Google Scholar 

  192. Lee GY, Kim BS, Seo YT, et al. Phase II study to topotecan and cisplatin in advanced hepatocellular carcinoma. Korean J Int Med 2003;18:104–108.

    CAS  Google Scholar 

  193. Feun LG, Savaraj N, Hung S, et al. A phase II trial of recombinant leukocyte interferon plus doxorubicin in patients with hepatocellular carcinoma. Am J Clin Oncol 1994;17:393–395.

    Article  PubMed  CAS  Google Scholar 

  194. Feun LG, O’Brien C, Molina E, et al. Recombinant leukocyte interferon, doxorubicin, and 5FUDR in patients with hepatocellular carcinoma: a phase II trial. J Cancer Res Clin Oncol 2003;129:17–20.

    PubMed  CAS  Google Scholar 

  195. Bokemeyer C, Kynast B, Harstrick A, et al. No synergistic activity of epirubicin and interferon-alpha 2b in the treatment of hepatocellular carcinoma. Cancer Chemother Pharmacol 1995;35:334–338.

    Article  PubMed  CAS  Google Scholar 

  196. Bobbio-Pallavicini E, Porta C, Moroni M, et al. Epirubicin and etoposide combination chemotherapy to treat hepatocellular carcinoma patients: a phase II study. Eur J Cancer 1997;33:1784–1788.

    Article  PubMed  CAS  Google Scholar 

  197. Kajanti MJ, Pyrhonen SO. Phase II intravenous study of epirubicin with 5-fluorouracil in patients with advanced hepatocellular carcinoma. Eur J Cancer 1991;27:1620–1622.

    Article  PubMed  CAS  Google Scholar 

  198. Engstrom PF, Levin B, Moertel CG, et al. A phase II trial of tamoxifen in hepatocellular carcinoma. Cancer (Phila) 1990;65:2641–2643.

    Article  PubMed  CAS  Google Scholar 

  199. Riestra S, Rodriguez M, Delgado M, et al. Tamoxifen does not improve survival of patients with advanced hepatocellular carcinoma. J Clin Gastroenterol 1998;26:200–203.

    Article  PubMed  CAS  Google Scholar 

  200. Anonymous. Tamoxifen in treatment of hepatocellular carcinoma: a randomised controlled trial. CLIP Group (Cancer of the Liver Italian Programme) [see comment]. Lancet 1998;352:17–20.

    Google Scholar 

  201. Cheng AL, Chen YC, Yeh KH, et al. Chronic oral etoposide and tamoxifen in the treatment of far-advanced hepatocellular carcinoma. Cancer (Phila) 1996;77:872–877.

    Article  PubMed  CAS  Google Scholar 

  202. Cheng AL, Yeh KH, Fine RL, et al. Biochemical modulation of doxorubicin by high-dose tamoxifen in the treatment of advanced hepatocellular carcinoma. Hepatogastroenterology 1998;45:1955–1960.

    PubMed  CAS  Google Scholar 

  203. Melia WM, Johnson PJ, Williams R. Controlled clinical trial of doxorubicin and tamoxifen versus doxorubicin alone in hepatocellular carcinoma. Cancer Treat Rep 1987;71:1213–1216.

    PubMed  CAS  Google Scholar 

  204. Schachschal G, Lochs H, Plauth M. Controlled clinical trial of doxorubicin and tamoxifen versus tamoxifen monotherapy in hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2000;12:281–284.

    PubMed  CAS  Google Scholar 

  205. Yuen MF, Poon RT, Lai CL, et al. A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma. [see comment] [erratum appears in Hepatology 2003;37:489]. Hepatology 2002;36:687–691.

    Article  PubMed  CAS  Google Scholar 

  206. O’Reilly EM, Stuart KE, Sanz-Altamira PM, et al. A phase II study of irinotecan in patients with advanced hepatocellular carcinoma. Cancer (Phila) 2001;91:101–105.

    Article  PubMed  CAS  Google Scholar 

  207. Lin J, Shiu W, Leung WT, et al. Phase II study of high-dose ifosfamide in hepatocellular carcinoma. Cancer Chemother Pharmacol 1993;31:338–339.

    Article  PubMed  CAS  Google Scholar 

  208. Cheirsilpa A, Leelasethakul S, Auethaveekiat V, et al. High-dose mitomycin C: activity in hepatocellular carcinoma. Cancer Chemother Pharmacol 1989;24:50–53.

    Article  PubMed  CAS  Google Scholar 

  209. Colleoni M, Nole F, Di Bartolomeo M, et al. Mitoxantrone in patients affected by hepatocellular carcinoma with unfavorable prognostic factors. Oncology 1992;49:139–142.

    PubMed  CAS  Google Scholar 

  210. Colleoni M, Buzzoni R, Bajetta E, et al. A phase II study of mitoxantrone combined with beta-interferon in unresectable hepatocellular carcinoma. Cancer (Phila) 1993;72(11):3196–3201.

    Article  PubMed  CAS  Google Scholar 

  211. Chao Y, Chan WK, Birkhofer MJ, et al. Phase II and pharmacokinetic study of paclitaxel therapy for unresectable hepatocellular carcinoma patients. Br J Cancer 1998;78:34–39.

    PubMed  CAS  Google Scholar 

  212. Hsu C, Chen CN, Chen LT, et al. Low-dose thalidomide treatment for advanced hepatocellular carcinoma. Oncology 2003;65:242–249.

    Article  PubMed  CAS  Google Scholar 

  213. Wall JG, Benedetti JK, O’Rourke MA, et al. Phase II trial to topotecan in hepatocellular carcinoma: a Southwest Oncology Group study. Invest New Drugs 1997;15:257–260.

    Article  PubMed  CAS  Google Scholar 

  214. Falkson G, Burger W. A phase II trial of vindesine in hepatocellular cancer. Oncology 1995;52:86–87.

    PubMed  CAS  Google Scholar 

  215. Kitagawa Y, Nagino M, Kamiya J, et al. Lymph node metastases from hilar cholangiocarcinoma: audit of 110 patients who underwent regional and paraaortic node dissection. Ann Surg 2001;233:385–392.

    Article  PubMed  CAS  Google Scholar 

  216. Launois B, Terblanche J, Lakehal M, et al. Proximal bile duct cancer: high resectability rate and 5-year survival. Ann Surg 1999;230:266–275.

    Article  PubMed  CAS  Google Scholar 

  217. Iwatsuki S, Todo S, Marsh JW, et al. Treatment of hilar cholangiocarcinoma (Klatskin tumors) with hepatic resection or transplantation. J Am Coll Surg 1998;187:358–364.

    Article  PubMed  CAS  Google Scholar 

  218. Miyazaki H, Ito H, Nakagawa K, et al. Aggressive surgical approaches to hilar cholangiocarcinoma: hepatic or local resection? Surgery (St. Louis) 1998;123:131–136.

    PubMed  CAS  Google Scholar 

  219. Eckel F, Lersch C, Assmann G, et al. Toxicity of a 24-hour infusion of gemcitabine in biliary tract and pancreatic cancer: a pilot study. Cancer Invest 2002;20:180–185.

    Article  PubMed  CAS  Google Scholar 

  220. Malik IA, Aziz Z. Prospective evaluation of efficacy and toxicity of 5-FU and folinic acid (Mayo Clinic regimen) in patients with advanced cancer of the gallbladder. Am J Clin Oncol 2003;26:124–126.

    Article  PubMed  CAS  Google Scholar 

  221. Bhargava P, Jani CR, Savarese DM, et al. Gemcitabine and irinotecan in locally advanced or metastatic biliary cancer: preliminary report. Oncology (Huntingt) 2003;17:23–26.

    PubMed  Google Scholar 

  222. Kuhn R, Hribaschek A, Eichelmann K, et al. Outpatient therapy with gemcitabine and docetaxel for gallbladder, biliary, and cholangio-carcinomas. Invest New Drugs 2002;20:351–356.

    Article  PubMed  CAS  Google Scholar 

  223. Choi CW, Choi IK, Seo JH, et al. Effects of 5-fluorouracil and leucovorin in the treatment of pancreatic-biliary tract adenocarcinomas. Am J Clin Oncol 2000;23:425–428.

    Article  PubMed  CAS  Google Scholar 

  224. Mani S, Sciortino D, Samuels B, et al. Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced biliary carcinoma. Invest New Drugs 1999;17:97–101.

    Article  PubMed  CAS  Google Scholar 

  225. Eckel F, Lersch C, Assmann G, et al. Phase II trial of low-dose cyclophosphamide, leucovorin, high-dose 5-fluorouracil 24-hour continuous infusion and tamoxifen in advanced biliary tract cancer. Ann Oncol 2000;11:762–763.

    Article  PubMed  CAS  Google Scholar 

  226. Kajanti M, Pyrhonen S. Epirubicin-sequential methotrexate-5-fluorouracil-leucovorin treatment in advanced cancer of the extrahepatic biliary system. A phase II study. Am J Clin Oncol 1994;17:223–226.

    Article  PubMed  CAS  Google Scholar 

  227. Taal BG, Audisio RA, Bleiberg H, et al. Phase II trial of mitomycin C (MMC) in advanced gallbladder and biliary tree carcinoma. An EORTC Gastrointestinal Tract Cancer Cooperative Group Study. Ann Oncol 1993;4:607–609.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, Mayo Clinic College of Medicine, Rochester, MN, USA

    Michael L. Kendrick MD (Assistant Professor) & David M. Nagorney MD (Professor)

  2. First Department of Internal Medicine, University of Mainz, Mainz, Germany

    Annette Grambihler MD (Staff)

  3. Department of Medicine, Mayo Clinic College of Medicine, Rochester, MN, USA

    Gregory J. Gores MD (Professor)

  4. Department of Oncology, Mayo Clinic College of Medicine, Rochester, MN, USA

    Steven Alberts MD, MPH (Associate Professor)

Authors
  1. Michael L. Kendrick MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Annette Grambihler MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gregory J. Gores MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Steven Alberts MD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. David M. Nagorney MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Surgery Oncology, Department of Surgery, University of Michigan, Ann Arbor, MI, USA

    Alfred E. Chang MD (Hugh Cabot Professor of Surgery and Chief) (Hugh Cabot Professor of Surgery and Chief)

  2. Breast Oncology Program, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA

    Daniel F. Hayes MD (Clinical Director) (Clinical Director)

  3. Department of Cardiothoracic Surgery, New York University School of Medicine and Comprehensive Cancer Center, New York, NY, USA

    Harvey I. Pass MD (Professor and Chief of Thoracic Surgery and Head) (Professor and Chief of Thoracic Surgery and Head)

  4. Thoracic Oncology, New York University School of Medicine and Comprehensive Cancer Center, New York, NY, USA

    Harvey I. Pass MD (Professor and Chief of Thoracic Surgery and Head) (Professor and Chief of Thoracic Surgery and Head)

  5. Department of Medicine, Harvard Medical School, USA

    Richard M. Stone MD (Associate Professor and Clinical Director) (Associate Professor and Clinical Director)

  6. Adult Leukemia Program, Dana-Farber Cancer Institute, Boston, MA, USA

    Richard M. Stone MD (Associate Professor and Clinical Director) (Associate Professor and Clinical Director)

  7. Division of Cancer Prevention and Control Research, Jonsson Comprehensive Cancer Center at UCLA, USA

    Patricia A. Ganz MD (American Cancer Society Clinical Research Professor, Director and Professor) (American Cancer Society Clinical Research Professor, Director and Professor)

  8. Schools of Public Health and Medicine, University of California, Los Angeles, Los Angeles, CA, USA

    Patricia A. Ganz MD (American Cancer Society Clinical Research Professor, Director and Professor) (American Cancer Society Clinical Research Professor, Director and Professor)

  9. Department of Radiation Oncology, University Hospitals of Cleveland, Case Western Reserve University, Cleveland, OH, USA

    Timothy J. Kinsella MD (Vincent K. Smith Professor and Chairman) (Vincent K. Smith Professor and Chairman)

  10. Department of Medicine, University of Wisconsin Comprehensive Cancer Center, Madison, WI, USA

    Joan H. Schiller MD (Melanie Heald Professor of Medical Oncology) (Melanie Heald Professor of Medical Oncology)

  11. Health Media Research Laboratory, Department of Health Behavior and Health Education, University of Michigan School of Public Health, USA

    Victor J. Strecher PhD, MPH (Professor and Director and Associate Director) (Professor and Director and Associate Director)

  12. Cancer Prevention and Control, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA

    Victor J. Strecher PhD, MPH (Professor and Director and Associate Director) (Professor and Director and Associate Director)

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Springer Science+Business Media, Inc.

About this chapter

Cite this chapter

Kendrick, M.L., Grambihler, A., Gores, G.J., Alberts, S., Nagorney, D.M. (2006). Cancer of the Liver and Bile Ducts. In: Chang, A.E., et al. Oncology. Springer, New York, NY. https://doi.org/10.1007/0-387-31056-8_44

Download citation

  • DOI: https://doi.org/10.1007/0-387-31056-8_44

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-0-387-24291-0

  • Online ISBN: 978-0-387-31056-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation